Clinical Trials Logo

Cognitive Dysfunction clinical trials

View clinical trials related to Cognitive Dysfunction.

Filter by:

NCT ID: NCT02942888 Completed - Clinical trials for Mild Cognitive Impairment

The Effects of Nicotinamide Adenine Dinucleotide (NAD) on Brain Function and Cognition

NAD
Start date: November 30, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the effects of Niagen (nicotinamide riboside, vitamin B3), on NAD levels, brain function including cognition and blood flow in people diagnosed with mild cognitive impairment (MCI).

NCT ID: NCT02940457 Withdrawn - Clinical trials for Mild Cognitive Impairment

Cognitive Ability Training for Seniors With Mild Cognitive Impairment

MICE
Start date: November 1, 2017
Phase: N/A
Study type: Interventional

This study investigates the beneficial effects of prefrontal brain stimulation (with transcranial direct current stimulation [tDCS]) during working memory training in seniors with mild cognitive impairments.The placebo-controlled double blinded study includes 50 elderly patients which will be randomized into verum or sham tDCS.

NCT ID: NCT02936401 Completed - HIV Infection Clinical Trials

Mindfulness Based Stress Reduction for Older Adults With HIV Associated Neurocognitive Disorders

Start date: March 30, 2015
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the efficacy of Mindfulness Based Stress Reduction (MBSR) to alleviate stress, anxiety, and depressive symptoms, and improve attention among patients aged 60 or older who suffer from HIV-associated neurocognitive disorders (HAND) and have maximized treatment options.

NCT ID: NCT02936219 Active, not recruiting - Clinical trials for Cognitive Impairment

The PREWEAN Study. Weaning of Preterm Infants During the First Year of Life.

PREWEAN
Start date: April 2016
Phase:
Study type: Observational

In this Austrian observational study preterm infants born with a birth weight <1500 g and a gestational age <32 weeks will be investigated at the neonatal outpatient clinic. Infants will be stratified according their feeding regimen (breast, formula and combined feeding) and their introduction of solid foods (early complementary feeding group: <17th week of life corrected for prematurity, late complementary feeding group: ≥17th week of life corrected for prematurity). Nutrient intakes and anthropometric parameters will be assessed at term, 6 weeks, 12 weeks, 6 months, 9 months and 12 months - all corrected for prematurity and with 40, 54 and 66 months.

NCT ID: NCT02931877 Completed - Clinical trials for Postoperative Cognitive Dysfunction

Comparison of Postoperative Outcome After Sevoflurane and Propofol Anaesthesia

Start date: October 2016
Phase: Phase 4
Study type: Interventional

As the investigators know, postoperative cognitive dysfunction (POCD) is a fairly well-documented clinical phenomenon, which affect patients' short-term and long-term outcome. Most patients will receive general anesthesia and cardiopulmonary bypass (CPB) during cardiac valvular surgery. Inhalation sevoflurane based and propofol based anesthesia are most commonly used strategy for general anesthesia. At present, it was unknown that which one is better in providing cerebral protection effect for patients undergoing cardiac valvular surgery with CPB. The current study aimed to explore the possible difference.

NCT ID: NCT02931136 Not yet recruiting - Clinical trials for Mild Cognitive Impairment

Early Diagnosis and Early Treatment of Alzheimer's Disease Based on Senile Plaque Imaging

Start date: November 2019
Phase: Phase 4
Study type: Interventional

The purpose of this study is based on the Flutemetamol-PET senile plaque imaging to investigate the peripheral blood biochemical and brain MRI imaging biomarkers and to research completely independent intellectual property rights neuropsychological test tool for the MCI due to AD. At the same time, the investigators will study the efficacy and safety of early treatment of MCI due to AD by Huperzine A in 52 weeks.

NCT ID: NCT02929979 Completed - Clinical trials for Alcohol Use Disorder

Cognitive Remediation for Alcohol Use Disorder and Posttraumatic Stress Disorder

Start date: January 1, 2015
Phase: N/A
Study type: Interventional

The project will examine whether a computerized neuroscience-based cognitive training program can improve cognitive functioning and recovery outcomes among Veterans with Alcohol Use Disorder and co-occurring PTSD. Information from this study will help determine the malleability of cognitive dysfunction, an established risk factor for poor recovery outcomes in this population. Improved functional outcomes can decrease risk of chronic impairment and ultimately help affected individuals live richer, more productive lives. Web-based treatment technologies may increase the reach and impact of treatment, and foster patient recovery in cases where staffing, space, acceptability of counseling, and transportation are barriers. Findings may also support expanding use of existing, highly-accessible cognitive remediation technologies to other vulnerable clinical populations.

NCT ID: NCT02928692 Recruiting - Prostate Cancer Clinical Trials

Minocycline Attenuate Postoperative Cognitive Dysfunction and Delirium

MAPOCD
Start date: November 2016
Phase: Phase 3
Study type: Interventional

Postoperative cognitive dysfunction (POCD) and postoperative delirium occurs mainly in aged patients. POCD and POD may increase the mortality and morbidity. However, the mechanism of POCD is not clear yet and no effective therapy method was proved. According to previous study, the neuroinflammation is the main reason both for POCD and POD. Minocycline is a tetracycline derivative. Due to it's lipophilic structure, it is easy to pass through blood brain barrier and attenuate neuroinflammation. It's neuroprotective effects has been proven in many experimental animal models such as Alzheimer's disease, Huntington's disease and Parkinson's syndrome. In present study, the investigators hypothesized that minocycline would attenuate the incidence of POCD and POD in the aged patients.

NCT ID: NCT02928211 Recruiting - Clinical trials for Mild Cognitive Impairment

Aftobetin-HCl and Fluorescence Detection Measured by Sapphire II to Determine the Number and Timing of Administrations

Start date: July 2016
Phase: Phase 1
Study type: Interventional

This is an open-label study to evaluate Aftobetin-HCl and florescence detection as measured by the Sapphire II device. Performance of Part I of the study has been completed (15 subjects received a single administration of Aftobetin HCL followed by Sapphire II measurements) and indicated that 3 administrations of Aftobetin-HCl are necessary. For Part II, a second group of up to 30 subjects (CN =10 and mild AD or MCI =20) will receive three Aftobetin HCL administrations. If three administrations of Aftobetin HCL are optimal, up to an additional 30 MCI and 30 mild AD subjects will be entered. The purpose of the study as Part II is performed is to determine the ability of the Sapphire II device to detect B-amyloid in the lens of the eye in subjects with Mild Cognitive Impairment (MCI), and mild Alzheimer's Disease (AD) after three Aftobetin-HCl administrations. Subjects with Normal Cognition (CN) will also be tested to further establish that subjects who are highly unlikely to have B-amyloid deposits in the lens of the eye will have close to baseline post ligand fluorescent uptake value (FUV) using the Sapphire II technology.

NCT ID: NCT02927522 Recruiting - Clinical trials for Rheumatoid Arthritis

Donepezil Attenuate Postoperative Cognitive Dysfunction

DAPOCD
Start date: September 1, 2018
Phase: Phase 3
Study type: Interventional

Postoperative cognitive dysfunction (POCD) occurs mainly in aged patients. POCD may increase the mortality and morbidity. However, the mechanism of POCD is not clear yet and no effective therapy method was proved. According to our previous study, the central cholinergic system impaired by the anesthesia and surgery play a very important role in the POCD and donepezil an acetylcholinesterase inhibitor can prevent the POCD after isoflurane anesthesia in aged mice. Donepezil is a commercial medicine used for the Alzheimer Disease, which is tolerable and has minimal adverse events. In present study a multi-center randomized case control study was conducted and we hypothesized that donepezil attenuate the POCD.